Background: In observational studies, patients with HIV have higher levels of soluble ST2 (sST2), galectin-3, and growth differentiation factor-15 (GDF-15) than non-HIV controls. As statins exert pleiotropic immunomodulatory effects that may affect markers of myocardial fibrosis, the objective of the current study is to determine whether biomarkers of myocardial fibrosis reflecting subclinical pathology may be modified by statin therapy in patients with HIV.
INTRODUCTION
Patients living with HIV (PLHIV) have an increased risk of myocardial infarction, heart failure, and heightened inflammation. [1] [2] [3] [4] We have previously shown that PLHIV have higher soluble ST2 (sST2) and galectin-3 than non-HIV controls. 5 sST2, believed to be a soluble decoy receptor to its cell membrane bound counterpart, has been associated with atherosclerosis, fibrosis, inflammation, and immune activation possibly through inhibiting ST2/interleukin-33 (IL-33) signaling. [6] [7] [8] [9] Growth differentiation factor-15 (GDF-15), a member of the transforming growth factor-b (TGF-b) superfamily, is secreted in the heart in response to ischemia and pressure overload [10] [11] [12] with levels measured in blood predicting cardiac events and mortality in the general population. 13 Both GDF-15 and sST2 were found to be elevated and associated with mortality in PLHIV. 14 Galectin-3, a marker of inflammation and cardiac fibrosis, has been shown to predict incident heart failure and increased left ventricular mass in the Framingham Offspring and Framingham Heart studies. 15 Statin therapy, a potent lipid lowering therapy, also significantly reduces measures of inflammation independent of lowdensity lipoprotein (LDL) lowering. 16 Statins in animal models can inhibit cardiac fibrosis independent of LDLcholesterol lowering believed to be mediated through Rho kinases (ROCKs) inhibition. ROCK-mediated effects are believed to be responsible for several of the pleotropic effects of statins including limiting cardiac fibrosis, hypertrophy, and pathologic remodeling in response to adverse stimuli such as angiotensin II. 17 In PLHIV, who have a greater burden of cardiac fibrosis than age and risk factor-matched controls, 18 the influence of high potency statin therapy on these markers could provide important insights into the potential clinical effects of statin therapy.
METHODS

Study Design
This study was a single center 12-month randomized, double-blind, placebo-controlled clinical trial of atorvastatin vs. placebo, showing effects on coronary plaque volume as previously reported. 19 However, markers of fibrosis were not assessed previously nor are these results available from other statin studies in HIV. HIV-infected subjects 18-60 years of age, on stable antiretroviral therapy (ART) with no changes in ART regimen in the preceding 6 months, and LDLcholesterol between 70 and 130 mg/dL (not meeting clinical guidelines criteria at the time for statin therapy) were enrolled. Exclusion criteria were previous history of cardiovascular disease (CVD), evidence of subclinical obstructive atherosclerotic CVD, defined by presence of 1 or more plaques on coronary computed tomography angiography with significant stenosis (.50% left main stenosis or .70% stenosis in any major vessel), concurrent use of a statin, aspartate aminotransferase, or alanine aminotransferase 3 times greater than the upper limit of normal and/or treatment for active liver disease, renal disease, and/or creatinine .1.5 mg/dL, as well as other criteria as previously described. 19 Patients were randomized in 1:1 ratio to either atorvastatin (starting at dose of 20 mg per day and escalating to 40 mg per day at 3-month visit if study drug was well tolerated) or placebo groups. All subjects received standardized lifestyle counseling based on National Cholesterol Education Program (NCEP) guidelines. All participants provided written informed consent and the study was approved by the MGH institutional review board. The trial is registered on ClinicalTrials.gov (NCT00965185).
For the current analysis, we measured markers of myocardial fibrosis with inflammatory mechanisms (sST2, galectin-3, and GDF-15) previously found to be elevated in HIV that we hypothesized may be reduced by statin therapy. Secondarily, we sought to assess whether baseline and changes in sST2, galectin-3, and GDF-15 related to baseline and changes in circulating markers of inflammation and oxidized LDL.
Biomarker Assessments
The following soluble protein biomarkers were measured at baseline and at 12 months for this analysis: sST2, for adverse cardiac remodeling and tissue fibrosis; galectin-3, for fibrosis and inflammation; and GDF-15. Enzyme-linked immunosorbent assay measurements for the following biomarkers were performed in strict accordance with manufacturer instructions: sST2 (Critical Diagnostics, San Diego, CA); galectin-3 (BGMedicine, Waltham, MA); and GDF-15 (R&D Systems, Minneapolis, MN). For sST2, the assay measurement range was 3.1-200.0 ng/mL; the interassay coefficient of variations ranged from 8.9% to 7.3% at values between 20 and 79 ng/mL. The galectin-3 assay's measurement range is 0.96-130 ng/mL; interassay coefficient of variations ranged from ,10% to 15% at values between 6 and 70 ng/mL. For GDF-15, typical interassay imprecision is 6.0% at 225 pg/mL GDF-15 and 5.6% at 900 pg/mL. All laboratory assessments were obtained after a 12-hour fast and other analytes were measured as previously reported. 19, 20 
Statistical Analysis
Comparisons between the 2 groups (atorvastatin vs. placebo) were performed using Student t test for normally distributed continuous variables and Wilcoxon rank-sum test if the distribution was nonnormal. To assess changes within each group, paired t test or Wilcoxon signed rank test was performed, depending on normality of distribution. Pearson correlation coefficient was used to assess relationships of sST2, galectin-3, and GDF-15 with other parameters. Twotailed probability values are reported, and statistical significance was assumed when P , 0.05. Mean values and SDs are reported to describe changes in continuous variables with normal distribution; otherwise, medians and interquartile ranges (IQRs) are used. For analysis of GDF-15, two outliers based on the Dixon criteria were excluded. All statistical analyses were performed using SAS JMP version 11 (SAS Institute, Cary, NC).
RESULTS
Characteristics of the Participants at Baseline
Eighty-one HIV-infected participants underwent screening for this study. Forty participants were randomized to atorvastatin or placebo. Demographic, clinical characteristics, lipids, immunologic, and systemic inflammatory markers of these 40 study participants have previously been described and are also shown in Supplemental Digital Content Table, http://links.lww.com/ QAI/B119. Participants were all on ART and most patients had undetectable viremia with similar immunological and virological indices between groups. At baseline, there were no significant differences in cardiac immunologic, inflammatory, or cardiac biomarkers between the groups (Supplemental Digital Content Table, http://links.lww.com/QAI/B119 and Table 1 ). After randomization, 1 of 21 patients in the placebo group and 2 of 19 in the statin group discontinued and did not have a 12-month evaluation.
Changes in Cardiac Biomarkers in the Atorvastatin Group vs. Placebo
Changes in sST2 were 20.3 ng/mL (IQR 24.2 to 2.1) with atorvastatin vs. an increase of 1.2 ng/mL (0.6-4.7) with placebo (P = 0.04 for comparison of change between groups) ( Table 1 and Fig. 1 ). Atorvastatin tended to lower GDF-15 with a change in GDF-15 of 219 6 425 pg/mL with atorvastatin vs. a 262 6 507 pg/mL increase with placebo, but this did not reach statistical significance (P = 0.08 for comparison of change between groups) ( Table 1) . By contrast, galectin-3 did not change significantly between groups with atorvastatin vs. placebo treatment.
Correlation With Changes in Cardiac Biomarker Levels
In all patients, the change in sST2 positively correlated with changes in monocyte activation markers sCD14 (r = 0.63, P , 0.0001) and MCP-1 (r = 0.52, P = 0.0009), hsIL-6 (r = 0.58, P = 0.0002), oxLDL (r = 0.49, P = 0.002), %CD14 + CD16 + monocytes (r = 0.46, P = 0.03), and change in GDF-15 (r = 0.54, P = 0.0008), whereas the change in GDF-15 was positively correlated with changes in galectin-3 (r = 0.51, P = 0.002), MCP-1 (r = 0.42, P = 0.01), sCD14 (r = 0.45, P = 0.007), hsIL-6 (r = 0.47, P = 0.005), and change in %CD14+CD16 + monocytes (r = 0.52, P = 0.02).
DISCUSSION
In the current analysis, we found sST2 increased significantly more in the placebo-treated patients than atorvastatin-treated PLHIV, suggesting a potential effect of statins to mitigate ongoing fibrosis in this population. We also demonstrate that overall changes in sST2 are related to changes in monocyte activation markers.
Cardiac fibrosis is increased in patients with HIV. 18 Statin therapy is being increasingly contemplated for PLHIV, because of effect on subclinical atherosclerotic disease, but little is known regarding effects of statin therapy on markers of cardiac fibrosis in HIV. One marker of importance in this regard is sST2. sST2 has been shown to be higher in PLHIV compared with noninfected individuals. 5, 21 Furthermore, sST2 has also been shown to be associated with cardiovascular dysfunction and strongly predictive all-cause mortality in PLHIV. 14 In the general population, sST2 predicts cardiovascular events and all-cause mortality, 13 and also predicts worse clinical outcomes in patients after acute myocardial infarction 22 and in patients with chronic heart failure. 23 ST2 is an interleukin-1 family receptor involved in inflammatory and immune responses. 8 The ST2 gene encodes for 2 isoforms of the ST2 protein: transmembrane ST2L, which is primarily expressed on dendritic cells, mast cells, macrophages, and T helper cells, and secreted soluble ST2 (sST2). 6 The functional ligand of ST2 is interleukin-33 (IL-33), which has a variety of biological functions including its role as an alarmin which responds to cellular stress and infection. 24 IL-33 is released by myocardial endothelial cells and gut epithelial cells, and signals through binding to the ST2 receptor to mediate both proinflammatory and anti-inflammatory mechanisms. [25] [26] [27] IL-33/ST2 signaling has been shown to reduce the development of atherosclerosis in mice, presumably through the induction of a Th1-to-Th2 shift and the production of antioxidized LDL (ox-LDL) and IL-5 antibodies. 6 Decreased production of ox-LDL antibodies may result from elevated sST2 levels, which would limit IL-33/ST2 signaling and elevate oxLDL, offering a possible explanation for the positive correlation we observed between sST2 and ox-LDL. IL-33 signaling also has demonstrated antifibrotic effects in the myocardium; however, endothelial cell production of IL-33 in response to myocardial pressure overload can induce a systemic inflammatory state. 25 IL-33/ST2 signaling is controlled by sST2, which acts as a decoy receptor to limit IL-33 activity, preventing the myocardial and vascular protective benefits of IL-33. 25 As such, elevated sST2 levels are associated with adverse prognosis in CVD and have been identified as a biomarker in heart disease, fibrosis, atherosclerosis, and inflammation. 8 IL-33 signaling through ST2 activates T cells and promotes Th2 lymphocyte responses, and has been shown to activate alternatively activated macrophages in ST2-deficient mice. 28, 29 The role of IL-33/ST2 signaling in monocyte and macrophage activation suggests that increased sST2 would result in increased inflammation.
The effect of statin therapy on IL-33/ST2 signaling has not yet been clearly elucidated, although previous studies have demonstrated that treatment of human umbilical vein endothelial cells with statins affects expression of IL-33 and ST2 mRNA expression. DNA microarray studies have shown that atorvastatin and pitavastatin decrease ST2 mRNA expression. 30 These data suggest that statin therapy may directly affect the expression of IL-33 and ST2s. 31 We demonstrated that the change in sST2 related significantly to the change hs-IL6 as well as to changes in MCP-1, sCD14 with statin therapy, further confirming the relationships between sST2 and markers of monocyte activation consistent with the known role of IL-33/ST2 signaling in monocyte and macrophage activation. Furthermore, change in sST2 related to the change in oxidized LDL. It is uncertain whether statins' effects on lowering oxidized LDL may potentially mediate the reduction in sST2; however, these relationships suggest that statins may reduce sST2 through direct anti-inflammatory effects on immune cells and possibly also through lowering of oxidized LDL. Given the previous strong association of sST2 with diastolic dysfunction and increased mortality in PLHIV prospective studies of statins such as the pitavastatin in the randomized trial to prevent vascular events in HIV (REPRIEVE, NCT02344290) will provide the opportunity to determine whether a statinmediated decrease in sST2 is independently associated with a reduced incidence of heart failure and death as well as nonfatal atherosclerotic CVD.
Another well-validated cardiac biomarker assessed in the current study is GDF-15, which we found to increase significantly over time in the placebo group but not in the atorvastatin group. GDF-15, also known as MIC-1, PTGF-b, PDF, PLAB, NAG-1, and PL74 is a member of the TGF-b superfamily 10 that is expressed in the heart and other tissues in response to proinflammatory cytokines and cardiovascular stress-related stimuli. [10] [11] [12] Although the exact mechanisms are unclear, these effects seem to be mediated through Aktand SMAD2/3-related signaling pathways. 11, 12 Levels of GDF-15 have been shown to correlate with cardiovascular mortality, and all-cause mortality in the general population. [32] [33] [34] In the Framingham heart study, both GDF-15 and sST2 were found to be predictive of death, heart failure, and major cardiac events. 13 Although GDF-15 is increased in settings of inflammation and cardiovascular injury, Bonaca et al 35 found no significant difference in the effect of high-dose vs. low-dose statin therapy on GDF-15 levels in the PROVE-IT TIMI 22 trial. Their null findings may be because both groups had received statin therapy, so it would be harder to detect a difference. Although we did not find a significant decrease in GDF-15 with atorvastatin in our study either, our data suggest that statin therapy may help to prevent increases in GDF-15 in the HIV population which has increased GDF-15 at baseline. To the best of our knowledge, no previous studies have examined the effects of statins on GDF-15 compared with placebo in HIV.
Only 1 previous study has assessed GDF-15 in HIVinfected participants. In that prospective cohort study, GDF-15 levels were elevated in patients with HIV compared with controls, were associated with pulmonary hypertension and independently predicted all-cause mortality in the HIV group. 14 In our study, we demonstrated an increase in GDF-15 in the placebo group over 1 year and showed that atorvastatin tended to lower GDF-15 compared with placebos. GDF-15 may be induced by lipopolysaccharide in intestinal myofibroblasts. 36, 37 Further research is needed to determine whether GDF-15 is increased in HIV by similar mechanisms.
In our study, we observed significant correlations between change in GDF-15 and markers of immune activation and inflammation, suggesting that GDF-15 may act primarily through immune and inflammatory pathways. 38 In addition, we found the changes in GDF-15 and sST2 to be positively correlated. This finding is consistent with other studies 13, 39, 40 and suggests that GDF-15 and sST2 may act through a common biological pathway.
This study has limitations, including its small size. Despite this, results from this randomized placebo-controlled trial are informative regarding potential effects of statins on myocardial fibrosis in HIV, which may be modulated by effects on immune pathways. Data from our randomized trial suggest for the first time that statin therapy may prevent ongoing progression of fibrosis as indicated by sST2 in PLHIV and thus help to preserve the cardioprotective mechanisms of the IL-33/ST2 signaling system. Statin therapy may also help to prevent the progression of rise in GDF-15. Further larger studies are now needed to confirm these findings and ultimately determine whether such changes relate to improved measurements of cardiac fibrosis, inflammation, and events and whether PLHIV with higher sST2 or GDF-15 should be targeted for such studies.
